Cargando…

Analysis of CDK12 alterations in a pan‐cancer database

BACKGROUND: CDK12 inactivation leading to increased neoantigen burden has been hypothesized to sensitize tumors to immune checkpoint inhibition. Pan‐cancer data regarding the frequency of CDK12 alterations are limited. We aimed to characterize CDK12 alterations across all cancer types through real‐w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Elizabeth, Cabal, Angelo, Javier‐DesLoges, Juan, Patel, Devin, Panian, Justine, Lee, Suzanna, Shaya, Justin, Nonato, Taylor, Xu, Xiaojun, Stewart, Tyler, Rose, Brent, Shabaik, Ahmed, Cohen, Ezra, Kurzrock, Razelle, Tamayo, Pablo, McKay, Rana R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817093/ https://www.ncbi.nlm.nih.gov/pubmed/34898046 http://dx.doi.org/10.1002/cam4.4483

Ejemplares similares

Low-Value Prostate-Specific Antigen Screening in Older Males
por: Kalavacherla, Sandhya, et al.
Publicado: (2023)

Asymptomatic detection of SARS‐CoV‐2 among cancer patients receiving infusional anti‐cancer therapy
por: Shaya, Justin, et al.
Publicado: (2021)

EDITORIAL COMMENT
por: Javier-DesLoges, Juan, et al.
Publicado: (2022)

Disparities in germline testing among racial minorities with prostate cancer
por: Weise, Nicole, et al.
Publicado: (2021)

Targeting G(1)/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
por: Kato, Shumei, et al.
Publicado: (2021)

Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance
por: Nelson, Tyler J., et al.
Publicado: (2021)

Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues
por: Li, Alex M., et al.
Publicado: (2019)

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting
por: Joshi, Rushikesh S., et al.
Publicado: (2022)

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
por: Louie, Bryan H., et al.
Publicado: (2022)

ALK fusions in the pan-cancer setting: another tumor-agnostic target?
por: Shreenivas, Aditya, et al.
Publicado: (2023)

Disparities in Telemedicine Utilization for Urology Patients During the COVID-19 Pandemic
por: Javier-DesLoges, Juan, et al.
Publicado: (2022)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act
por: Javier-DesLoges, Juan F., et al.
Publicado: (2021)

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
por: Shaya, Justin, et al.
Publicado: (2023)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
por: Kato, Shumei, et al.
Publicado: (2021)

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
por: Pham, Timothy V., et al.
Publicado: (2020)

Molecular landscape of pancreatic cancer: implications for current clinical trials
por: Heestand, Gregory M., et al.
Publicado: (2015)

Click chemistry, 3D-printing, and omics: the future of drug development
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications
por: Cohen, Philip R., et al.
Publicado: (2015)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Fool’s gold, lost treasures, and the randomized clinical trial
por: Stewart, David J, et al.
Publicado: (2013)

Cutaneous Metastatic Cancer: Carcinoma Hemorrhagiectoides Presenting as the Shield Sign
por: Cohen, Philip R, et al.
Publicado: (2021)

Nailing the Diagnosis: Onychotillomania in Patients With Artificial Nails—An Underrecognized Phenomenon?
por: Cohen, Philip R, et al.
Publicado: (2022)

Dermatologic Disease-Directed Targeted Therapy (D(3)T(2)): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology
por: Cohen, Philip R., et al.
Publicado: (2022)

Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series
por: Cohen, Philip R, et al.
Publicado: (2023)

Systematic Pan-Cancer Analysis Identifies CDK1 as an Immunological and Prognostic Biomarker
por: Yang, Yaqi, et al.
Publicado: (2022)

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment
por: Okamura, Ryosuke, et al.
Publicado: (2021)

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies
por: Gupta, Diviya, et al.
Publicado: (2022)

Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
por: Louie, Bryan H., et al.
Publicado: (2022)

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
por: Helsten, Teresa, et al.
Publicado: (2015)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
por: Khemlina, Galina, et al.
Publicado: (2017)

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
por: Liu, Sariah, et al.
Publicado: (2016)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lugqk960p9hm162j4lu42i65t8